Premium
Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML‐RARα isoforms: a study of the PETHEMA group
Author(s) -
González M.,
Barragán E.,
Bolufer P.,
Chillón C.,
Colomer D.,
Borstein R.,
Calasanz M. J.,
GómezCasares M. T.,
Villegas A.,
Marugán I.,
Román J.,
Martín G.,
Rayón C.,
Debén G.,
Tormo M.,
DíazMediavilla J.,
Esteve J.,
GonzálezSan Miguel J.,
Rivas C.,
PérezEquiza K.,
GarcíaSanz R.,
Capote F. J.,
Ribera J. M.,
Arias J.,
León A.,
Sanz M. A.
Publication year - 2001
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2001.02915.x
Subject(s) - medicine , acute promyelocytic leukemia , gastroenterology , white blood cell , hematology , cd34 , biology , gene , retinoic acid , stem cell , biochemistry , genetics
Of 167 newly diagnosed acute promyelocytic leukaemia patients, 83 patients were long ( L )‐ form (50%), eight variable ( V ) ‐form (5%) and 76 short ( S )‐fo r m (45%). The V‐form and S‐form groups presented a significantly higher percentage of patients with white blood cell counts > 10 × 10 9 /l ( P < 0·05). The S‐form cases displayed a significantly higher number of cases with M3v microgranular features ( P = 0·005) and CD34 expression ( P < 0·0001). There were no differences between the three isoforms in complete remission (CR) rate (overall CR 90%), but the 3‐year disease‐free survival was lower for V‐form cases than it was for L ‐ and S‐form cases (62% vs. 94% and 89%, P = 0·056). We conclude that the V‐form and S‐form types are associated with some negative prognostic features at diagnosis. However, our data were only able to demonstrate an association with adverse prognosis in the V‐form type and, moreover, as the number of cases was limited, needs to be confirmed in large, uniformly treated series.